Colin Lowery

  • Citations Per Year
Learn More
BACKGROUND A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma had been identified as a predictor of superior long-term outcome in some--but not all--studies. METHODS To determine if the parameter of M protein reduction was of value in the relapsed and/or refractory setting, retrospective landmark(More)
Levels of brain neurotransmitters and their metabolites, as well as concentrations of enzymes associated with their synthesis and metabolism, fluctuate during the day in patterns defined as circadian. The present study examined these rhythms in albino rats exposed to 60-Hz electric fields. Thirty-six animals were exposed to a 39 kV/m field for 4 weeks, 20(More)
Raltitrexed (Tomudex), a classical folate antagonist, is a selective inhibitor of thymidylate synthase (TS). It has significant single-agent activity in metastatic colorectal cancer. Severe life-threatening toxicity related to the administration of 5-fluorouracil and leucovorin is described in two patients, both of whom were not deficient in(More)
8591 Background: An early response in MM results in rapid improvement in symptoms and may benefit outcomes. To investigate the relationship between rapid response and outcomes, we retrospectively evaluated early reduction in M protein (MProt) in a trial of pegylated liposomal doxorubicin + bortezomib (PLD+B) vs B alone in relapsed/refractory multiple(More)
  • 1